Open session of the standing technical committee of the EUFMD- 2004

Page 485

Appendix 79 POSTER SESSION Chairperson: Dr Nilay UNAL Rapporteur : Dr Stéphan ZIENTARA Dr Georgi GEORGIEV At the Open Session of the EUFMD Research Group Meeting 17 posters were presented. These posters deal with -Epidemiology (1) -FMDV structure (1) -FMD vaccines (2) -Pathogenesis (4) -Diagnosis (molecular diagnosis-7) (serological diagnosis-2) Recommendations of the Poster Session The reporting group would like to underline the fact that the decision of the FMD Research Group to organise such a poster session was a good initiative. On the basis of the presented posters in this session the reporting group makes following recommendations: -

necessıty to reinforce the surveillance of FMD around the world in particular in Africa develop studies on the structure of the FMDV proteins in order to better understand their fonctions and develop antiviral molecules develop reagents (recombinant antıbodies or monoclonal antibodies) for diagnosıs or studies on pathogenesis develop and reinforce studies on the pathogenesis of FMD and the interactions virus\cells develop studies on the immune response against FMDV in susceptible species develop studies on the molecular diagnosis of FMDV (real-time PCR, loop mediated amplification, rolling circle amplification) develop tools for rapid and reliable diagnostic method for serological diagnosis of FMD necessity of comparative studies, validatıon and standardisatıon new diagnostic methods

Summary of the posters presented Identification of FMDV replication in cells within the foot and tongue epithelia S. Durand1*, C. Murphy1, S. Alexandersen1,2. Pirbright Laboratory, Institute for Animal Health, Ash Rd, Woking, Surrey, GU24 0NF, UK. 2 Present address: Danish Institute for Food and Veterinary Research, Department of Virology, Lindholm, DK4771 Kalvehave, Denmark. 1

This study deals with identification of FMDV replication sites by in situ hybridisation in pigs. In situ hybridization (ISH) has been used to detect FMDV RNA in tissues from infected pigs. A digoxigeninlabelled RNA probe corresponding to a coding part of the RNA-dependent RNA polymerase (3D) genomic region was prepared. Results indicate that the basal cell appears to be the cell type demonstrating the highest signal for the detection of the FMDV positive sense RNA in both tongue and foot epithelium. The detection FMDV positive sense RNA showed very strong signal in basal cells (especially in foot lesions). Mouth lesions showed in general less signals than in foot lesions.Although the stratum spinosum cells show more signs of cytolysis than the basal cells, the FMDV RNA signal in the stratum spinosum cells was more diffuse and less concentrated. These results are strongly suggesting that the basal cells could be the early replication site of FMDV in vivo. Laser Micro-Dissection studies of FMDV infection in pigs R. Ahmed1*, S. Durand1, Z. Zhang1, M. Quan1, C. Murphy1 and S. Alexandersen2 Institute for Animal Health, Pirbright, Woking, Surrey, GU24 ONF, U.K. 2 Danish Institute for Food and Veterinary Research, Department of Virology, Lindholm, DK-4771 Kalvehave, Denmark 1

The objective of this study was to isolate and quantify foot-and-mouth disease virus (FMDV) in the different epithelium cell-types in order to observe potential differences in FMDV RNA distribution in specific tissues. Laser Micro-Dissection (LMD) was carried out on frozen sections from selected tissues of infected pigs. After RNA extraction the samples were tested for FMDV and 18S ribosomal RNA (as a RNA marker) by real time quantitative RT-PCR.

476


Turn static files into dynamic content formats.

Create a flipbook

Articles inside

Appendix 82

17min
pages 492-500

Appendix 77

22min
pages 468-476

Appendix 78

25min
pages 477-484

Appendix 79

14min
pages 485-489

Appendix 81

1min
page 491

Appendix 80

1min
page 490

Appendix 76

12min
pages 464-467

Appendix 75

1min
page 463

Appendix 64

10min
pages 412-414

Appendix 72

13min
pages 455-460

Appendix 73

1min
page 461

Appendix 65

1min
page 415

Appendix 67

1min
page 424

Appendix 63

34min
pages 401-411

Appendix 62

2min
page 400

Appendix 54

8min
pages 361-363

Appendix 61

15min
pages 394-399

Appendix 55

11min
pages 364-366

Appendix 59

1min
page 385

Appendix 60

20min
pages 386-393

Appendix 56

1min
page 367

Appendix 42

21min
pages 270-276

Appendix 52

10min
pages 350-352

Appendix 50

21min
pages 330-339

Appendix 46

2min
page 307

Appendix 37

7min
pages 241-243

Appendix 38

7min
pages 244-246

Appendix 41

2min
page 269

Appendix 40

15min
pages 255-268

Appendix 36

16min
pages 236-240

Appendix 35

15min
pages 231-235

Appendix 34

25min
pages 224-230

Appendix 28

2min
page 198

Appendix 31

10min
pages 212-215

Appendix 29

16min
pages 199-203

Appendix 33

3min
pages 221-223

Appendix 27

1min
page 197

Appendix 26

27min
pages 188-196

Appendix 25

12min
pages 182-187

Appendix 23

8min
pages 168-171

Appendix 22

28min
pages 158-167

Appendix 15

2min
page 113

Appendix 16

7min
pages 114-116

Appendix 20 EMEA paper extract - Recommendations for tests for induction of antibodies to NSP antigens by FMD vaccines

4min
pages 144-145

Appendix 19

18min
pages 136-143

Appendix 14

4min
page 112

Appendix 13

10min
pages 107-111

Appendix 5

2min
page 64

Appendix 12

9min
pages 104-106

Appendix 3

9min
pages 47-49

Appendix 4

26min
pages 50-63

Appendix 8

12min
pages 77-80

Appendix 2

8min
pages 43-46

Open Session

6min
pages 39-42

Closed Session

2min
pages 37-38

Item 11 – Persistent and subclinical infections – diagnostic and surveillance issues

3min
page 33

Item 15 – Managing the decision-making process in control of FMD and in the priority setting of research and development

3min
page 36

Item 14 – Regulatory compliance

2min
page 35

Item 10 – International issues

3min
page 32

Item 9 – Novel vaccines

3min
page 31

Item 7 – Optimisation of conventional vaccines

3min
page 29

Item 4 – Managing diagnostic demands

3min
page 27

Item 8 – Regulatory issues affecting FMD vacine selection and use

3min
page 30

Item 3 – Transmission and its control

3min
page 26

3.4.2 Post-vaccination serosurveillance (PVS) for presence of FMD infected animals

3min
page 16

Item 1 – Recent findings in molecular epidemiology of FMDV

3min
page 24

Item 2 – Surveillance: for what purpose and how much is enough?

3min
page 25

4.2 Collection of sera/specimens for validation of DIVA tests for detection of animals received from SAT virus infection

3min
page 20
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.